Refractory subacute cutaneous lupus erythematous responding to a single course of belimumab: a new anti-BLyS human monoclonal antibody.
暂无分享,去创建一个
[1] Susan S. Kim,et al. Belimumab in systemic lupus erythematosus: an update for clinicians , 2012, Therapeutic advances in chronic disease.
[2] M. Petri,et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.
[3] M. Petri,et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. , 2008, Arthritis and rheumatism.
[4] L. Iaccarino,et al. Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. , 2006, Annals of the rheumatic diseases.